Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 185380
                    [Title] => Trailblazer
                    [Summary] => When Hilarion  Henares insisted on buying two  coronary stents,  Johnson & Johnson Medical Phils. managing director Bayani Santos, Jr. was placed in a quandary. "Larry Henares is an informed heart patient. At that time, he insisted on buying our  Cypher Sirolimus-eluting stent , which had not yet gotten approval from  the Bureau of Food and Drugs. We had to get a special one-time dispensation from BFAD," he said.


                    [DatePublished] => 2002-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1488513
                    [AuthorName] => Margaret Jao-Grey 
                    [SectionName] => Business As Usual
                    [SectionUrl] => business-as-usual
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 174812
                    [Title] => Device offers longer-term solution for coronary artery disease
                    [Summary] => A breakthrough heart device now answers the long-time woes of patients suffering from coronary artery disease (CAD). 


Johnson & Johnson Medical Phils. recently launched its Cypher Sirolimus-eluting Stent in local hospitals. This is the first and only drug-coated stent approved by the Bureau of Food and Drugs (BFAD) for treatment of narrowed coronary arteries.


An industry first, the Cypher Sirolimus-eluting Stent is a new medical device that addresses one of the most stubborn problems in coronary artery disease treatment – the potential for restenosis. 


                    [DatePublished] => 2002-09-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

CYPHER SIROLIMUS

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 185380
                    [Title] => Trailblazer
                    [Summary] => When Hilarion  Henares insisted on buying two  coronary stents,  Johnson & Johnson Medical Phils. managing director Bayani Santos, Jr. was placed in a quandary. "Larry Henares is an informed heart patient. At that time, he insisted on buying our  Cypher Sirolimus-eluting stent , which had not yet gotten approval from  the Bureau of Food and Drugs. We had to get a special one-time dispensation from BFAD," he said.


                    [DatePublished] => 2002-11-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1488513
                    [AuthorName] => Margaret Jao-Grey 
                    [SectionName] => Business As Usual
                    [SectionUrl] => business-as-usual
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 174812
                    [Title] => Device offers longer-term solution for coronary artery disease
                    [Summary] => A breakthrough heart device now answers the long-time woes of patients suffering from coronary artery disease (CAD). 


Johnson & Johnson Medical Phils. recently launched its Cypher Sirolimus-eluting Stent in local hospitals. This is the first and only drug-coated stent approved by the Bureau of Food and Drugs (BFAD) for treatment of narrowed coronary arteries.


An industry first, the Cypher Sirolimus-eluting Stent is a new medical device that addresses one of the most stubborn problems in coronary artery disease treatment – the potential for restenosis. 


                    [DatePublished] => 2002-09-05 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Trailblazer

By Margaret Jao-Grey  | November 25, 2002 - 12:00am

When Hilarion Henares insisted on buying two coronary stents, Johnson & Johnson Medical Phils. managing director Bayani Santos, Jr. was placed in a quandary. "Larry Henares is an informed heart patient....

Business As Usual

Device offers longer-term solution for coronary artery disease

September 5, 2002 - 12:00am

A breakthrough heart device now answers the long-time woes of patients suffering from coronary artery disease (CAD). Johnson & Johnson Medical Phils. recently launched its Cypher Sirolimus-eluting Stent in...

Science and Environment